Unparalleled Group of Advisers
Cellceutix Scientific Advisor, Dr. Emil Frei III recently commented on the latest developments at Cellceutix. He stated, “What Cellceutix is doing with Kevetrin™ can lead to a groundbreaking moment in the world of oncology. In my career, including my tenure as Chief of Medicine at National Cancer Institute, I have seen countless companies throughout the world striving to bridge the gap between damaged or mutated p53 and carcinomas with little to no success. p53 can hold a vital key to the next generation of chemotherapy. Cellceutix’s discovery of Kevetrin™, which has been shown to reactivate p53 in a non-genotoxic manner, is a very promising advance in the fight against cancer.” Dr. Frei has unparalleled experience in the development of new cancer drugs. He is often referred to as the “Father of the Cure for Childhood Leukemia” because of his collaborative work with Dr. Emil J. Freireich.
